ArticleNature communications2025
Machine learning-supported framework for the classification of mpox infection and MVA immunization from multiplexed serology data.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Serological differentiation between Mpox infection and vaccine-induced immunity: a mini-review.Frontiers in immunology · 2026Review
- Machine learning-supported framework for the classification of mpox infection and MVA immunization from multiplexed serology data.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 2022 global mpox outbreak highlighted the risk of zoonotic diseases establishing sustained transmission in human populations and underscored the need for accurate serological tools to monitor orthopoxvirus exposure. However, cross-reactive antibodies induced by Modified Vaccinia Ankara (MVA) vaccination make it difficult to discriminate between monkeypox virus (MPXV) infection and vaccination-induced immunity. Here we present a machine learning (ML)-assisted bead-based serological multiplex assay that distinguishes MPXV infection from MVA vaccination and pre-immune sera by targeting antibody responses to 15 poxviral antigens. Of the six algorithms tested, the Gradient Boosting Classifier (GBC) achieves the highest performance (F1 = 0.83) in sera from the 2022 outbreak and from a follow-up epidemiological cohort of at-risk men who have sex with men (MSM; n = 1,260). In an independent validation cohort (n = 143), GBC (F1 = 0.70) robustly detects MPXV infections, including breakthrough cases, with 88% specificity and 92% sensitivity. Integrating ML with high-dimensional serology enables accurate cross-sectional classification of orthopoxvirus immune status and provides a scalable framework for mpox serosurveillance and outbreak preparedness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.